180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its receipt of a Notice of Allowance from the United States Patent and Trade Office for application 16/661,769 “Method for Reducing Post-Operative Cognitive Dysfunction (‘POCD’).” According to the update, 300,000 elderly people suffer a hip fracture in the U.S. each year with an estimated similar numbers across Europe and 1.3 million worldwide. Approximately 25% of these patients develop a major complication, delirium, in which they become confused and lose awareness of themselves and their surroundings. Patients with delirium have a two-fold greater risk of dying and are four times more likely to require admission to a care home, and a significant number suffer long-term loss of cognitive function or post-operative delirium or POCD. While there is currently no approved therapeutic for preventing the development of delirium/POCD, Professors Marc Feldmann and Jagdeep Nanchahal, co-founders of 180 Life Sciences, and their colleagues, found in a preclinical model that inflammatory mediators released at the time of surgery to fix a broken bone was associated with memory loss in animals. Administration of anti-TNF before surgery resulted in improved outcomes. 180 Life Sciences has exclusively licensed intellectual property on this important discovery, with patents now issued in the U.S. and U.K./EU and initial coverage to 2031. The scientific findings suggest that administration of an anti-TNF antibody before surgery may reduce or prevent the development of delirium in this important and large group of elderly patients. These critical findings form the basis for a randomized controlled clinical trial 180 Life Sciences is planning with the team at the University of Oxford for elderly patients who are undergoing hip fracture surgery in the U.K. “The issuance of these additional patent assets further strengthens the IP portfolio governing and protecting our programs,” said Dr. James Woody, CEO of 180 Life Sciences. “We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies.”
To view the full press release, visit https://ibn.fm/OhNra
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
